CJC-1295 (without DAC) 10mg + Ipamorelin 10mg

Ipamorelin’s high selectivity for GHSR-1a, with minimal cross-activation of parallel hormone pathways, makes it the standard GHRP paired with a GHRH analogue in this type of research. The non-DAC form is substantially shorter-acting than the albumin-binding DAC-modified form, supporting research designs where discrete, repeated receptor engagement across the research window is the objective.

Sourcing both compounds as a single-supplier bundle provides batch consistency across the research protocol, with both peptides tested against the same documentation standard by the same independent laboratory.

Every compound in the Somatic Axis Complex is independently tested by Janoshik laboratory. HPLC purity is confirmed at ≥98%, with LC-MS molecular identity verification for both CJC-1295 Without DAC and Ipamorelin. Batch-specific Certificates of Analysis are publicly accessible for both compounds before purchase.

For laboratory handling purposes, both lyophilised peptides may be reconstituted using BP-grade bacteriostatic water and stored at -20°C, avoiding repeated freeze-thaw cycles.

For complete mechanism detail on each compound, see the Ipamorelin and CJC-1295 research guides on the Ascend Peptides UK blog, or the GH axis research peptides category page.

The two compounds target mechanistically distinct receptors on the same pituitary somatotroph cells: CJC-1295 Without DAC acts at the GHRH receptor (GHRHR) through the Gs-cAMP-PKA pathway, while Ipamorelin acts at GHSR-1a (the ghrelin receptor) through the Gq-PLC-IP3-calcium pathway. This receptor-level and second-messenger-level separation is the analytical foundation of the combined protocol — each compound functions as a fully independent variable within the same research design.